Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://link.springer.com/content/pdf/10.1007/s11154-023-09833-1.pdf
Reference142 articles.
1. Basolo F, Macerola E, Poma AM, Torregrossa L. The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma. Endocrine. 2023;80:470–6. https://doi.org/10.1007/s12020-023-03336-4.
2. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Cancer. 2005;103(7):1330–5. https://doi.org/10.1002/cncr.20936.
3. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol. 2010;22:486–97.
4. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022; 33(4): 406 – 15. https://doi.org/10.1016/j.annonc.2021.12.014.
5. Zhao X, Wang JR, Dadu R, Busaidy N, Xu L, Learned K, Chasen N, Vu T, Maniakas A, Eguia A, Diersing J, Gross N, Goepfert R, Lai S, Hofmann M, Ferrarotto R, Lu C, Gunn G, Spiotto M, Subbiah V, Williams M, Cabanillas M, Zafereo M. Surgery after BRAF-directed therapy is associated with improved survival in BRAF V600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid. 2023;33(4):484–91. https://doi.org/10.1089/thy.2022.0504.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Trends in Mortality for Anaplastic Thyroid Cancer: Have We Made Progress?;Journal of Surgical Research;2024-10
2. An overview of the contemporary diagnosis and management approaches for anaplastic thyroid carcinoma;World Journal of Clinical Oncology;2024-06-24
3. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro;International Journal of Molecular Sciences;2024-06-19
4. Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer;Biomedicines;2024-06-10
5. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis;Endocrine;2024-05-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3